Tanvex BioPharma Inc (6541.TW) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Taiwan · ISIN KYG8676P1037
Tanvex BioPharma Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 34.68 m TWD | 400.97 m TWD |
| Gross profit | 8.29 m TWD | -440.71 m TWD |
| Operating income | -1.36 bn TWD | -1.39 bn TWD |
| EBIT | -1.33 bn TWD | -1.39 bn TWD |
| Net income | -1.38 bn TWD | -1.50 bn TWD |
| Diluted EPS – continuing operations | -8.90 TWD | -6.13 TWD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.
More stocks
- United Orthopedic (4129.TWO)
- Adimmune Corp (4142.TW)
- Genesis Technology (6221.TWO)
- Alkindo Naratama Tbk (ALDO.JK)
- Kepler Weber S.A (KEPL3.SA)
- DingZing Advanced Materials Inc. (6585.TW)
- Xi S And D Inc (317400.KS)
- Central Omega Resources Tbk PT (DKFT.JK)
- Solid FAB (SFAB.ST)
- Mediantechn (ALMDT.PA)
- Hsin Yung Chien Co Ltd (2114.TW)
- NG Energy International Corp. (GASX.TO)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.